It took many years for investigators to find an effective treatment that could extend survival beyond androgen deprivation therapy for patients with metastatic castration-resistant prostate cancer. The answer was found in the chemotherapy docetaxel in 2004. The next 13 years saw the approval of 8 treatments for the same disease